Akari Therap

Q2 FY2026 EarningsQ2 FY2026 results missed bottom-line expectations, with a Net Loss of $4.8M vs. the $3.6M consensus mean, and GAAP EPS of -$1.04 meeting the consensus figure. Revenue remains at $0 as the company focuses on IND-enabling activities for AKTX-101. The cash position was strengthened by $8.6M in financing, though R&D expenses rose 200% YoY to $2.1M to support development toward a planned mid-2027 Phase 1 trial.